← Patent-cliff monitor small molecule XDEMVY LOTILANER
Loss of exclusivity December 2038 latest FDA-listed patent expiry
Drug detail Brand name XDEMVY Active ingredient LOTILANER Strength 0.25% Dosage form SOLUTION/DROPS Route OPHTHALMIC Modality Small molecule FDA approval July 2023 Marketing status RX
Listed patents Patent Expires Type 11690827 December 2038 use U-3674 11690826 December 2038 use U-3674 11197847 December 2038 use U-3674 10835517 December 2038 use U-3674 12171750 December 2038 use U-3674 11752137 December 2038 product 12213964 December 2038 product 12364685 December 2038 product 8383659 January 2030 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.